A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
- Status
- COMPLETED
- Phase
- N/A
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Status
- RECRUITING
- Phase
- PHASE2
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
- Status
- COMPLETED
- Phase
- PHASE2
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
- Status
- COMPLETED
- Phase
- N/A
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
- Status
- COMPLETED
- Phase
- PHASE2
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
- Status
- COMPLETED
- Phase
- PHASE2
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1